Literature DB >> 9558030

Asymptomatic Helicobacter pylori gastritis is associated with increased sucrose permeability.

K Borch1, C Sjöstedt, U Hannestad, J D Söderholm, L Franzén, S Mårdh.   

Abstract

Our aim was to investigate whether there are changes in permeability to sucrose in asymptomatic Helicobacter pylori gastritis. Nineteen asymptomatic subjects with Helicobacter pylori-associated gastritis with no or mild mucosal atrophy and 19 age- and sex-matched normal controls were studied by peroral load of sucrose (100 g). The fraction of the given oral dose of sucrose excreted in urine was increased in subjects with Helicobacter pylori gastritis (median 0.08% versus 0.04% in controls). Sucrose excretion was not related to atrophy, intestinal metaplasia, or inflammation in the gastric mucosa. However, sucrose permeability was related to the degree of inflammatory (neutrophil) activity, since moderate activity was associated with higher sucrose excretion than mild activity (median 0.13% vs 0.07%). Asymptomatic Helicobacter pylori gastritis was associated with an increased sucrose permeability, which could be a sign of gastric mucosal leakage. This could have implications for the diseases and complications associated with Helicobacter pylori infection.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9558030     DOI: 10.1023/a:1018809913230

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  23 in total

1.  Neutrophil-derived oxidants mediate formyl-methionyl-leucyl-phenylalanine-induced increases in mucosal permeability in rats.

Authors:  C von Ritter; M B Grisham; M Hollwarth; W Inauen; D N Granger
Journal:  Gastroenterology       Date:  1989-09       Impact factor: 22.682

Review 2.  Intestinal permeability: an overview.

Authors:  I Bjarnason; A MacPherson; D Hollander
Journal:  Gastroenterology       Date:  1995-05       Impact factor: 22.682

3.  Possible role of Helicobacter pylori infection in early gastric cancer development.

Authors:  M Asaka; T Kimura; M Kato; M Kudo; K Miki; K Ogoshi; T Kato; M Tatsuta; D Y Graham
Journal:  Cancer       Date:  1994-06-01       Impact factor: 6.860

4.  Helicobacter pylori infection: independent risk indicator of gastric adenocarcinoma.

Authors:  L E Hansson; L Engstrand; O Nyrén; D J Evans; A Lindgren; R Bergström; B Andersson; L Athlin; O Bendtsen; P Tracz
Journal:  Gastroenterology       Date:  1993-10       Impact factor: 22.682

5.  IgA antiendomysium antibodies have a high positive predictive value for celiac disease in asymptomatic patients.

Authors:  E Grodzinsky; J Hed; T Skogh
Journal:  Allergy       Date:  1994-09       Impact factor: 13.146

Review 6.  Campylobacter pylori and peptic ulcer disease.

Authors:  D Y Graham
Journal:  Gastroenterology       Date:  1989-02       Impact factor: 22.682

Review 7.  The effect of Helicobacter pylori infection on gastric emptying of digestible and indigestible solids in patients with nonulcer dyspepsia.

Authors:  C S Chang; G H Chen; C H Kao; S J Wang; S N Peng; C K Huang
Journal:  Am J Gastroenterol       Date:  1996-03       Impact factor: 10.864

8.  A simple, non-invasive marker of gastric damage: sucrose permeability.

Authors:  L R Sutherland; M Verhoef; J L Wallace; G Van Rosendaal; R Crutcher; J B Meddings
Journal:  Lancet       Date:  1994-04-23       Impact factor: 79.321

9.  Gastric emptying and Helicobacter pylori infection in duodenal ulcer disease.

Authors:  F Perri; Y F Ghoos; B D Maes; B J Geypens; N Ectors; K Geboes; M I Hiele; P J Rutgeerts
Journal:  Dig Dis Sci       Date:  1996-03       Impact factor: 3.199

10.  Sucrose: a novel permeability marker for gastroduodenal disease.

Authors:  J B Meddings; L R Sutherland; N I Byles; J L Wallace
Journal:  Gastroenterology       Date:  1993-06       Impact factor: 22.682

View more
  9 in total

1.  Pathogenesis of increased sucrose permeability in H. pylori gastritis.

Authors:  D Y Graham
Journal:  Dig Dis Sci       Date:  2000-05       Impact factor: 3.199

2.  Helicobacter pylori activates myosin light-chain kinase to disrupt claudin-4 and claudin-5 and increase epithelial permeability.

Authors:  Jason P Fedwick; Tamia K Lapointe; Jonathan B Meddings; Philip M Sherman; Andre G Buret
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

3.  Effects of aspirin on gastroduodenal permeability in alcoholics and controls.

Authors:  Ashkan Farhadi; Ali Keshavarzian; Mary J Kwasny; Maliha Shaikh; Louis Fogg; Cynthia Lau; Jeremy Z Fields; Christopher B Forsyth
Journal:  Alcohol       Date:  2010-07-03       Impact factor: 2.405

Review 4.  Helicobacter pylori virulence and cancer pathogenesis.

Authors:  Yoshio Yamaoka; David Y Graham
Journal:  Future Oncol       Date:  2014-06       Impact factor: 3.404

Review 5.  Helicobacter pylori in intensive care: why we should be interested.

Authors:  Megan S Robertson; Robert L Clancy; John F Cade
Journal:  Intensive Care Med       Date:  2003-08-28       Impact factor: 17.440

Review 6.  Tight junction disruption: Helicobacter pylori and dysregulation of the gastric mucosal barrier.

Authors:  Tyler J Caron; Kathleen E Scott; James G Fox; Susan J Hagen
Journal:  World J Gastroenterol       Date:  2015-10-28       Impact factor: 5.742

Review 7.  Gastroretentive drug delivery systems for the treatment of Helicobacter pylori.

Authors:  Shan Zhao; Yan Lv; Jian-Bin Zhang; Bing Wang; Guo-Jun Lv; Xiao-Jun Ma
Journal:  World J Gastroenterol       Date:  2014-07-28       Impact factor: 5.742

8.  Helicobacter pylori PqqE is a new virulence factor that cleaves junctional adhesion molecule A and disrupts gastric epithelial integrity.

Authors:  Miguel S Marques; Ana C Costa; Hugo Osório; Marta L Pinto; Sandra Relvas; Mário Dinis-Ribeiro; Fátima Carneiro; Marina Leite; Ceu Figueiredo
Journal:  Gut Microbes       Date:  2021 Jan-Dec

Review 9.  Food Allergy and Helicobacter pylori Infection: A Systematic Review.

Authors:  Zheng Fei Ma; Noorizan A Majid; Yoshio Yamaoka; Yeong Yeh Lee
Journal:  Front Microbiol       Date:  2016-03-23       Impact factor: 5.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.